The Dementia Consortium is a global initiative to fund collaborative drug discovery into novel targets for the treatment of neurodegenerative diseases
This exciting project brings together the charity Alzheimer’s Research UK with MRC Technology, and pharmaceutical companies, Eisai and Lilly. It provides funding, expertise and resources to support novel targets and the development of therapeutics for dementia (including Alzheimer’s disease, dementia with Lewy bodies, tauopathies, vascular dementia, frontotemporal dementia and neurodegeneration-associated cognitive deficits).
The Consortium has put together a fund of £3 million to support the best academic research from both the UK and the rest of the world. Funding will be allocated to drug discovery projects (typically 2-3 years in duration) on targets to support target validation and explore the tractability of the target for drug discovery in collaboration with the Consortium members. Work will take place both within academia and at the MRC Technology’s dedicated small molecule and antibody drug discovery laboratories. Applicants and members of the Consortium will help progress successful projects from laboratories towards the clinic, with an ultimate goal of seeing new therapies delivered to patients.
If you are interested applying to the dementia consortium or would like to learn more about how this collaboration works please visit http://www.dementiaconsortium.org/ or email email@example.com